Loading stock data…
Virax Biolabs Group Limited (VRAX)
$2.63+0.01 (+0.19%)
Market ClosedLast close Sep 8
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Virax Biolabs Group Limited in the Healthcare sector is trading at $2.63 with a market capitalization of $2M. Wall Street consensus targets $25.00 (1 analysts), implying a +850.6% move over the next 12 months. The stock is currently near its 52-week low of $2.50, remaining 52.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +850.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United Stat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
28,341
Recent News
Virax Biolabs enters immune profiling product supply deal with Fosun
The collaboration initially focuses on tuberculosis research in Thailand, where Fosun has identified customer interest.
Why Did Virax Biolabs Stock Triple In One Session?
Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday’s premarket session, as the company has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, which is aimed at immune profiling. The agreement opens access to multiple Southeast Asian markets, potentially driving significant revenue growth for the company as it expands its commercial footprint. Virax Biolabs is developing in vitro diagnostic technologies for viral and imm
Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX)
Virax Biolabs Signs Multi-Country Supply PartnershipVirax Biolabs Group Limited (NASDAQ:VRAX) shares surged 100% on Thursday after the company announced an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product portfolio. The agreement covers six Southeast Asian markets—Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia—and establishes a framework for immediate product shipments through purchase orders, creating new near-term
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BC-Most Active Stocks
Avino Silver & Gold Mines Ltd. 3,734,622 5.7199